Dizal Pharmaceutical Co., Ltd.
Dizal Pharmaceutical Co., Ltd. has 1 licensing announcement in this dataset, dated 2026-07-14.
- Country / operating region
- China
- Ticker
- 查無
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- www.dizalpharma.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| Sunvozertinib; Zegfrovy | EGFR | small molecule | approved | 2026-07-14 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-07-14 | AstraZeneca | Sunvozertinib; Zegfrovy | USD 600m | 查無 | ≤ USD 900m | 查無 | — |
| Counterparty | Territory | Royalties |
|---|---|---|
| AstraZeneca | Worldwide | Tiered royalties on worldwide sales. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無